© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The experimental therapy improved liver inflammation, fibrosis and metabolic parameters in six months.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
Among those with primary biliary cholangitis, the investigational drug reduced alkaline phosphatase levels.
The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
